2025 France Cell And Gene Therapy Manufacturing Services Market Revenue Opportunities Report
Description
The 2025 France Cell And Gene Therapy Manufacturing Services Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cell and Gene Therapy Manufacturing Services Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Cell and Gene Therapy Manufacturing Services Market in France include Lonza, Catalent, Thermo Fisher Scientific, and Charles River Laboratories. These industry leaders provide comprehensive manufacturing solutions such as process development, GMP manufacturing, analytical testing, and regulatory support crucial for cell and gene therapy developers. Lonza is a global contract development and manufacturing organization (CDMO) with extensive expertise in viral vector and cell therapy production. Catalent specializes in advanced biologics, including gene therapy manufacturing and delivery technologies. Thermo Fisher Scientific offers innovative manufacturing platforms and quality control services, while Charles River supports early-stage development and GMP manufacturing of cell and gene therapies.
In addition to multinational CDMOs, France boasts significant local biotechs such as Genethon, GenSight Biologics, and Cellectis, which collaborate closely with public research institutes like Institut Imagine and Institut de la Vision. These companies leverage France's strong biotech ecosystem, supported by government initiatives and dedicated research clusters, to advance innovative gene and cell therapies. Genethon, a pioneer in gene therapy, has out-licensed technologies like adeno-associated virus (AAV) vectors to companies such as Avexis. Together, this combination of global manufacturing service providers and leading French biotech firms actively drives growth in France's $2.7 billion cell and gene therapy manufacturing market expected to grow substantially through 2033.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cell and Gene Therapy Manufacturing Services Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Cell and Gene Therapy Manufacturing Services Market in France include Lonza, Catalent, Thermo Fisher Scientific, and Charles River Laboratories. These industry leaders provide comprehensive manufacturing solutions such as process development, GMP manufacturing, analytical testing, and regulatory support crucial for cell and gene therapy developers. Lonza is a global contract development and manufacturing organization (CDMO) with extensive expertise in viral vector and cell therapy production. Catalent specializes in advanced biologics, including gene therapy manufacturing and delivery technologies. Thermo Fisher Scientific offers innovative manufacturing platforms and quality control services, while Charles River supports early-stage development and GMP manufacturing of cell and gene therapies.
In addition to multinational CDMOs, France boasts significant local biotechs such as Genethon, GenSight Biologics, and Cellectis, which collaborate closely with public research institutes like Institut Imagine and Institut de la Vision. These companies leverage France's strong biotech ecosystem, supported by government initiatives and dedicated research clusters, to advance innovative gene and cell therapies. Genethon, a pioneer in gene therapy, has out-licensed technologies like adeno-associated virus (AAV) vectors to companies such as Avexis. Together, this combination of global manufacturing service providers and leading French biotech firms actively drives growth in France's $2.7 billion cell and gene therapy manufacturing market expected to grow substantially through 2033.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
